Effects of neurofeedback on Cannabis Use Disorder (CUD)

Recruiting

Conditions: Cannabis use disorder
Mental and Behavioural Disorders
Mental and behavioural disorders due to use of cannabinoids

Registration Number: ISRCTN25526593

Lead Sponsor: Geneva University Hospitals - Addiction Unit

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 51

Inclusion Criteria

1. 34 patients with DSM-5 Diagnosis of Cannabis Use Disorder (CUD)
2. 17 sex and age-matched healthy controls
3. Aged between 18 and 50 years inclusive
4. Informed consent
5. Available to complete the study
6. Negative serum pregnancy test at screening (for women of childbearing potential)

Exclusion Criteria

1. Psychiatric disorder (other than CUD in CUD patients)
2. Neurological disorder
3. Significant medical condition such as cancer, liver disease, hepatic impairment, renal disease, neuroleptic malignant syndrome, non-traumatic rhabdomyolysis, pheochromocytoma, or glaucoma
4. Current treatment with antipsychotic or benzodiazepine or monoamine oxidase inhibitor
5. Metal implant
6. Participation in a research/clinical study involving radiation exposure in the past 12 months
7. Pregnancy
8. Breastfeeding
9. Lack of safe contraception

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Cannabis use, measured using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)<br>2. DA synthesis capacity and storage, measured using [18F]-FDOPA Ki uptake values (6-fluoro-L-DOPA (or Fluorodopa)<br><br>Measured at baseline (including PET scan), within one week of the two months treatment (including PET scan) and at two months follow-up (excluding PET scan)

Secondary Outcome Measures

Name	Time	Method
1. Time to smoke 1 gram of cannabis<br>2. Total scores on the Craving Experience Questionnaire and on the Dimensional Anhedonia Rating Scale<br>3. Theta/alpha power EEG measure<br>4. Stop-signal reaction time in the Stop Signal Task<br>5. Equivalence point in the Delay-Discounting Task<br>6. Average number of pumps delivered in the Balloon Analogue Risk Task<br><br>Measured at baseline (including PET scan), within one week of the two months treatment (including PET scan) and at two months follow-up (excluding PET scan)